• Market Capitalisation market-capitalisation-info $348 Mln
  • Price to Earnings Ratio price-to-earning 21.64
  • 12 Month Earnings monthly-earning $16 Mln

Vanda Pharmaceuticals Inc. (VNDA) Share Price

$3.55

As on 28-Nov-2023 16:00 EST

up-down-arrow $-0.01-0.28%

  • Prev Close info

    $3.56

  • Day's Openinfo

    $3.66

  • Today's Highinfo

    $3.66

  • Today's Lowinfo

    $3.50

  • Today's Volumeinfo

    853,077

  • 52 Week rangeinfo

    $3.30 - 11.04

Please wait...

Vanda Pharmaceuticals Inc. (VNDA) Stock Performance

YTD
1 Month
3 Months
1 Year
3 Years
5 Years
10 Years
Vanda Pharmaceuticals (VNDA)
-51.96 -14.46 -39.73 -65.96 -34.11 -31.37 -10.99
S&P BSE Sensex*
10.91 5.65 4.09 6.94 15.19 13.27 12.49
#
-- -- -- -- -- -- --
As on 28-Nov-2023  |  *As on 01-Dec-2023  |  #As on
2022
2021
2020
2019
2018
2017
2016
Vanda Pharmaceuticals (VNDA)
-52.90 19.41 -19.93 -37.20 71.40 -4.70 71.32
S&P BSE Sensex
4.44 21.99 15.75 14.38 5.87 27.91 1.95
S&P BSE Sensex
4.44 21.99 15.75 14.38 5.87 27.91 1.95

Valuation

Stock
Peer Median
Please wait...

Growth & Efficiency

Stock
Peer Median
Please wait...

Solvency

Is there a threat to this company's solvency in the future?

Financial Manipulation

Can creative accounting be detected through the financial numbers?

Vanda Pharmaceuticals Inc. (VNDA) Peer Comparison

search
search
search
search
    Please wait...

    Valuation Chart of Vanda Pharmaceuticals Inc. (VNDA)

      Please wait...
        Please wait...

        Financials

        Please wait...
        Please wait...
        Please wait...

        Shareholding Pattern

        Other details of Vanda Pharmaceuticals Inc. (VNDA)

        Founder, Pres, CEO & Chairman of The Board

        Dr. Mihael H. Polymeropoulos M.D.

        Sr. VP, CFO & Treasurer

        Mr. Kevin Patrick Moran

        Headquarters

        Washington, DC

        FAQs for Vanda Pharmaceuticals Inc. (VNDA)

        The total asset value of Vanda Pharmaceuticals Inc. (VNDA) stood at $ 738 Mln as on 31-Mar-23

        The share price of Vanda Pharmaceuticals Inc. (VNDA) is $3.55 (NASDAQ) as of 28-Nov-2023 16:00 EST. Vanda Pharmaceuticals Inc. (VNDA) has given a return of -34.11% in the last 3 years.

        Vanda Pharmaceuticals Inc. (VNDA) has a market capitalisation of $ 348 Mln as on 02-Jun-2023. As per Value Research classification, it is a company.

        The P/B ratio of Vanda Pharmaceuticals Inc. (VNDA) is 1.15 times as on 02-Jun-2023, a -0.55% premium to its peers’ median range of 2.54 times.

        The P/E (price to earnings) ratio of Vanda Pharmaceuticals Inc. (VNDA) is 21.64 times as on 02-Jun-2023.

        Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
        Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
        Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
        Step 4. Search for the Vanda Pharmaceuticals Inc. (VNDA) and enter the required number of quantities and click on buy to purchase the shares of Vanda Pharmaceuticals Inc. (VNDA).

        Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company's pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

        The CEO & director of Dr. Mihael H. Polymeropoulos M.D.. is Vanda Pharmaceuticals Inc. (VNDA), and CFO & Sr. VP is Mr. Kevin Patrick Moran.

        The promoters of Vanda Pharmaceuticals Inc. (VNDA) have pledged 0% of the total equity as on Dec-22.

        Vanda Pharmaceuticals Inc. (VNDA) Ratios
        Return on equity(%)
        3.04
        Return on capital employed(%)
        --
        Debt-to-equity ratio
        0
        Dividend yield(%)
        0

        Yes, TTM profit after tax of Vanda Pharmaceuticals Inc. (VNDA) was $16 Mln.

        Edit peer-selector-edit
        Please wait...
        Please wait...

        Key Facts

        • Market cap market-cap-information $348.11 Mln
        • Revenue (TTM)revenue-information $256.69 Mln
        • Earnings (TTM) earning-information $15.96 Mln
        • Cash date-information $501.50 Mln
        • Total Debt info $10.73 Mln
        • Insider's Holding 3.97%
        • Liquidity liquidity High
        • 52 Week range week-range $3.30 - 11.04
        • Shares outstanding share-outstanding 57,444,100
        • 10 Years Aggregate:

          CFO: $105.12 Mln

          EBITDA: $94.05 Mln

          Net Profit: $130.01 Mln

        About The Company

        • IPO Date 12-Apr-2006
        • Founder, Pres, CEO & Chairman of The Board Dr. Mihael H. Polymeropoulos M.D.
        • Sr. VP, CFO & Treasurer Mr. Kevin Patrick Moran
        • Listing key-listing NASDAQ: VNDA
        • Country United States
        • Headquarters headquarters Washington, DC
        • Website website https://www.vandapharma.com
        • Business

          Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake...  disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company's pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.  Read more

        Demystifying Stocks.

        At Value Research, we believe it's best to understand investments before diving in. And since 1990, we've been doing exactly that – helping & guiding lakhs of Indians with their investing journey. Join the journey.

        Sign Up for Free
        demystifying-mutual-fund

        What can Value Research do for you?

        solidify-your-fundamentals
        Solidify your fundamentals

        Learn the principles, mindset and tools you need to become a successful Mutual Fund and Stock investor from the masters who have been doing this for decades.

        track-all-your-investments
        Track all your investments

        Use India's most advanced investment tracker to track, analyse and get updates and insights on your investments.

        get-guidance-from-our-experts
        Get guidance from our experts

        Get an analysis of your portfolio along with actionable, general tips and insights, guidance on where to invest based on your goals, and experts' opinions on individual Mutual Funds and Stocks.

        get-access-to-exclusive-analytics
        Get access to exclusive analytics

        Value Research offers the most advanced and detailed data & analytics available on Mutual Funds and Stocks. Sign up and unlock the power yourself.

        Explore it yourself, for free

        Sign up and get access to:

        Unlimited access to advice from India's top experts

        The most comprehensive analysis of funds and stocks in India

        A holistic portfolio manager to help track all your investments easily

        And much more, like guides, tools, webinars, videos and eBooks.

        share-fund-plan-icon